Say hello to MassDevice +7, a bite-sized view of the top seven med-tech stories of the week. This latest feature of MassDevice.com’s coverage highlights our seven biggest and most influential stories from the week’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else this weekend, make sure you’re still in the know with MassDevice +7.
7. Masimo debuts 1st iPhone pulse oximeter
Medical device company Masimo unveils the iSpO2, the 1st Apple-approved pulse oximetry system compatible with iPods, iPhones and iPads.
6. Patients deserve their data | Guest Editorial by Joe Kiani, Masimo CEO
Masimo founder, board chairman and CEO Joe Kiani’s perspective on the "frustration many patients experience in trying to obtain their own health information, even from devices that are implanted inside their own bodies."
5. Politics and pessimism aren’t slowing down medical device tax repeal efforts
Spirits remain high for medical device industry advocates pushing for repeal of the 2.3% medtech tax, even in the face of political obstacles and in-group negativity.
Read more
4. Did Abiomed fly too close to the sun?
Abiomed’s dilemma is of its own making, Jefferies & Co. analyst Raj Denhoy tells MassDevice.com.
3. St. Jude shareholders accuse leadership of hiding Durata flaws
St. Jude Medical shareholders accuse the company and 3 executives of making false statements about the Durata defibrillator leads, which the plaintiffs say are prone to the same design flaws that led to the high-profile Riata recall.
2. The economy is just an excuse, says Allergan CEO David Pyott
"Innovation will always beat the economy, " Allergan chairman, president & CEO David Pyott tells attendees of MassDevice’s 2012 Big 100 Roundtable West in Newport Beach, Calif.
1. Medical device tax is here to stay, says AdvaMed’s James Mazzo
Efforts to repeal the medical device tax aren’t in vain, but they aren’t going to be successful in bringing down the levy, Abbot Medical Optics president and former AdvaMed board chairman James Mazzo says.
